Welcome to our dedicated page for Biofrontera news (Ticker: BFRIW), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (Nasdaq: BFRI, warrants Nasdaq: BFRIW) generates a steady flow of news centered on its dermatology-focused photodynamic therapy (PDT) business. Company press releases highlight commercial performance for Ameluz® PDT, progress in clinical development, and key corporate and regulatory milestones, offering context for both the underlying common stock and the associated BFRIW warrants.
Recent announcements describe record preliminary quarterly revenues, with management attributing growth to sales execution of Ameluz PDT and pricing changes. Biofrontera also reports on clinical trial milestones, such as database locks for a Phase 3 study in actinic keratosis on the extremities, neck and trunk and a Phase 2 study in moderate to severe acne vulgaris, as well as completion of a Phase 1 pharmacokinetics study in peripheral body areas. These updates are framed as supporting future regulatory submissions and potential label expansions.
News items further cover regulatory and intellectual property developments, including submission of a supplemental New Drug Application for superficial basal cell carcinoma and the completion of transfers of FDA approvals, patents, and trademarks for Ameluz and the RhodoLED lamp series to Biofrontera Inc. Corporate and financing news, such as the restructuring of the relationship with Biofrontera AG, preferred stock financings, and the divestiture of the Xepi antibiotic cream license, also appear in the company’s disclosures.
Visitors to this BFRIW news page can review earnings releases, business updates, clinical and regulatory announcements, and transaction-related press releases that collectively illustrate how Biofrontera is advancing its PDT platform in dermatology. For investors following the BFRIW warrants, these news items provide insight into the operating and strategic developments of the underlying issuer, Biofrontera Inc.
Biofrontera Inc. (Nasdaq: BFRI) reported third quarter revenues of $4.3 million, consistent with Q3 2021, and a 24% increase in revenues for the first nine months of 2022, totaling $18.5 million. The company raised $4.3 million from warrant exercises and strengthened its relationship with Biofrontera AG through an acquisition. Despite a net loss of $2.6 million for Q3 2022, significantly improved from $16.0 million in Q3 2021, adjusted EBITDA for the quarter was negative $5.0 million. The company anticipates revenue growth of 24% to 31% for 2022.
Biofrontera Inc. (Nasdaq: BFRI) will release its financial results for the three and nine months ending September 30, 2022, on November 14, 2022, prior to the U.S. market opening. A conference call is scheduled for the same day at 11:00 a.m. Eastern time to discuss these results and provide a business update. The call can be accessed via phone or a webcast, which will also be available for replay for 90 days. Biofrontera specializes in dermatological pharmaceuticals, notably in treating actinic keratoses and bacterial skin infections.
Biofrontera Inc. (Nasdaq: BFRI) announced the full exercise of options to purchase 2,623,365 ordinary shares of Biofrontera AG and acquired an additional 1,601,318 shares in a private exchange agreement. This brings Biofrontera Inc.'s total ownership to 4,224,683 shares, representing 7.45% of Biofrontera AG’s shares. CEO Erica Monaco emphasized the value of this transaction in strengthening the companies' relationship, noting that Biofrontera Inc. drives the majority of revenue from Biofrontera AG’s products in the dermatology market.
Biofrontera Inc. (Nasdaq: BFRI) has entered into private exchange agreements, issuing 3,148,042 new shares to holders of options to acquire shares of Biofrontera AG. This transaction reduces Biofrontera AG’s stake in Biofrontera Inc. from 34.63% to 29.96%, enhancing Biofrontera Inc.'s independence. The AG Options are immediately exercisable and will support ongoing clinical trials aimed at expanding the Ameluz® label in the U.S. market. The company plans to file a registration statement with the SEC for the shares' resale, further solidifying its market strategy.
Biofrontera Inc. (Nasdaq: BFRI) has appointed Fred Leffler as Chief Financial Officer, effective immediately. Leffler brings over 15 years of financial management experience, having previously worked with McKinsey, FTI Consulting, and general electric. His appointment coincides with the company's anticipated growth and capital requirements, and he aims to use data-driven methodologies to enhance revenue streams. The company specializes in dermatological treatments, primarily focusing on photodynamic therapy and antibiotics.
Biofrontera Inc. (Nasdaq: BFRI) will present at the LD Micro Main Event XV on October 26, 2022, at 4:00 PM Pacific Time at the Luxe Sunset Boulevard Hotel, Los Angeles, CA. CEO Erica Monaco will discuss the company’s dermatological products, focusing on photodynamic therapy and topical antibiotics for treating conditions like actinic keratoses and impetigo. A live webcast will be available at this link, and archived later on their website.
Biofrontera (Nasdaq: BFRI) announces its sponsorship of the Fall Clinical Dermatology Conference from October 20-23 in Las Vegas. As a Gold Industry Sponsor, the company will host an exhibit showcasing its flagship drug, Ameluz, and other products. An Advisory Board meeting will enhance education on photodynamic therapy (PDT) among dermatologists. Four research posters related to Ameluz will be presented, highlighting clinical trials and their findings. CEO Erica Monaco emphasizes the importance of these events in advancing knowledge and product visibility.
Biofrontera Inc. (Nasdaq: BFRI) announced the adoption of a limited duration shareholder rights plan to protect shareholder interests. This plan allows for the distribution of one preferred stock purchase right for each share of common stock to shareholders of record on October 24, 2022. The Board believes the current stock price does not reflect the company’s intrinsic value and aims to safeguard against unsolicited offers. The rights become exercisable upon acquisition of 20% or more of the common stock. The plan will expire on October 13, 2023.
Biofrontera Inc. (NASDAQ: BFRI) announced its participation in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series. The presentations will occur on October 14 at 10:00 AM EDT and October 18 at 1:00 PM CDT, discussing the latest investor presentation and allowing for a live Q&A session. CEO Erica Monaco stated this is the first of multiple events aimed at engaging investors across the U.S. Registrations are available through the provided links, with replays accessible on the company's investor page.
Biofrontera (Nasdaq: BFRI) reported preliminary unaudited product revenues for Q3 2022 at approximately $4.3 million, consistent with Q3 2021. For the first nine months of 2022, revenues are expected to be around $18.5 million, showing a 24% increase year-over-year. The company aims for at least a 30% revenue increase in 2022. CEO Erica Monaco highlighted ongoing efforts to enhance the adoption of PDT for actinic keratosis treatments, despite Q3 typically being a softer sales quarter. Full financial results will be disclosed in November 2022.